12/11/2024
3:15 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/15/2024
4:05 PM | 4D Molecular Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
11/14/2024
4:46 PM | 4D Molecular Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
11/14/2024
2:15 PM | 4D Molecular Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
11/14/2024
8:13 AM | 4D Molecular Therapeutics (Subject)
Deep Track Capital, LP (Filed by)
| Form SC 13G/A | |
11/13/2024
3:33 PM | 4D Molecular Therapeutics (Issuer)
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/13/2024
3:17 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
|
11/13/2024
3:08 PM | 4D Molecular Therapeutics (Subject)
BIOTECHNOLOGY VALUE FUND L P (Filed by)
| Form SC 13G/A | |
11/12/2024
11:12 AM | 4D Molecular Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/08/2024
1:17 PM | 4D Molecular Therapeutics (Subject)
BlackRock, Inc. (Filed by)
| Form SC 13G/A | |
11/06/2024
5:07 PM | 4D Molecular Therapeutics (Subject)
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
| Form SC 13G | |
11/04/2024
9:55 AM | 4D Molecular Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G | |
10/21/2024
3:11 PM | 4D Molecular Therapeutics (Subject)
BlackRock, Inc. (Filed by)
| Form SC 13G/A | |
09/18/2024
4:46 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
3:06 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/23/2024
5:04 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2024
7:22 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/17/2024
5:04 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/15/2024
5:13 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:46 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/10/2024
4:17 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/03/2024
4:11 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/01/2024
3:43 PM | 4D Molecular Therapeutics (Subject)
Bizily Scott (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/26/2024
4:07 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/25/2024
3:44 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144/A | |
06/24/2024
4:39 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/07/2024
4:04 PM | 4D Molecular Therapeutics (Filer)
| Form 424B5 | |
06/07/2024
4:07 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/23/2024
7:45 PM | 4D Molecular Therapeutics (Issuer)
Tomasello Shawn (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/23/2024
6:10 PM | 4D Molecular Therapeutics (Issuer)
GRAY SUSANNAH (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/23/2024
6:11 PM | 4D Molecular Therapeutics (Issuer)
MILLIGAN JOHN F (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/23/2024
6:12 PM | 4D Molecular Therapeutics (Issuer)
Miller-Rich Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/23/2024
6:16 PM | 4D Molecular Therapeutics (Issuer)
THEUER CHARLES (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/23/2024
6:17 PM | 4D Molecular Therapeutics (Issuer)
Chacko Jacob (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/20/2024
7:35 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
3:22 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
3:09 PM | 4D Molecular Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/18/2024
7:48 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/10/2024
3:05 PM | 4D Molecular Therapeutics (Filer)
| Form DEF 14A | |
04/10/2024
3:06 PM | 4D Molecular Therapeutics (Filer)
| Form DEFA14A | |
04/10/2024
3:07 PM | 4D Molecular Therapeutics (Filer)
| Form ARS | |
Why I'm telling friends to avoid gold stocks (Ad) Back in November, gold made a tiny move of 1.6%.
But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week.
It happened again in March. Gold nudged up 1.2%.
This time? A 104% overnight gain.
And in June? A 1% gold move turned into a 74% gain in two weeks.
Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now.
There's a more lucrative way to play the gold market as we enter a new breakout period.
It's all about catching what I call "Acceleration Cycles." And if you’d like to get your hands on this, here you go, the complete breakdown. |
04/03/2024
6:18 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/29/2024
3:52 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/20/2024
3:40 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
5:01 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
4:15 PM | 4D Molecular Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/21/2024
4:41 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
7:51 PM | 4D Molecular Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024
8:56 AM | 4D Molecular Therapeutics (Subject)
BIOTECHNOLOGY VALUE FUND L P (Filed by)
| Form SC 13G/A | |
02/14/2024
7:43 AM | 4D Molecular Therapeutics (Subject)
Deep Track Capital, LP (Filed by)
| Form SC 13G/A | |
02/13/2024
9:56 AM | 4D Molecular Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
02/12/2024
8:04 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/12/2024
7:22 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/08/2024
3:50 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/07/2024
7:32 PM | 4D Molecular Therapeutics (Issuer)
Kim Robert Young (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/07/2024
6:42 PM | 4D Molecular Therapeutics (Issuer)
Kim Robert Young (Reporting)
| Form 3/A | |
02/05/2024
4:27 PM | 4D Molecular Therapeutics (Filer)
| Form 424B5 | |
02/05/2024
3:35 PM | 4D Molecular Therapeutics (Filer)
| Form S-3ASR | |
01/25/2024
3:59 PM | 4D Molecular Therapeutics (Subject)
BlackRock Inc. (Filed by)
| Form SC 13G/A | |
01/23/2024
3:50 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/08/2024
3:15 PM | 4D Molecular Therapeutics (Subject)
VIKING GLOBAL INVESTORS LP (Filed by)
| Form SC 13G/A | |
01/08/2024
3:19 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/05/2024
4:44 PM | 4D Molecular Therapeutics (Issuer)
HALVORSEN OLE ANDREAS (Reporting)
Ott David C. (Reporting)
Shabet Rose Sharon (Reporting)
VIKING GLOBAL INVESTORS LP (Reporting)
Viking Global Opportunities GP LLC (Reporting)
Viking Global Opportunities Illiquid Investments Sub-Master LP (Reporting)
Viking Global Opportunities Parent GP LLC (Reporting)
Viking Global Opportunities Portfolio GP LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/05/2024
3:49 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/04/2024
4:48 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/04/2024
7:30 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/18/2023
4:16 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Free FDMT Stock Alerts